Iceland screens, treats, or prevents multiple myeloma (iStopMM) : a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

• Published in: Blood Cancer Journal
• Main Authors: Rögnvaldsson, Sæmundur, Love, Thorvardur Jon, Thorsteinsdottir, Sigrun, Reed, Elín Ruth, Óskarsson, Jón Þórir, Pétursdóttir, Íris, Sigurðardóttir, Guðrún Ásta, Viðarsson, Brynjar, Önundarson, Páll Torfi, Agnarsson, Bjarni A., Þorsteinsdóttir, Ingunn, Ólafsson, Ísleifur, Þórðardóttir, Ásdís Rósa, Eyþórsson, Elías, Jónsson, Ásbjörn, Björnsson, Andri S., Gunnarsson, Gunnar Þór, Pálsson, Runólfur, Indriðason, Ólafur Skúli, Gíslason, Gauti Kjartan, Ólafsson, Andri, Hákonardóttir, Guðlaug Katrín, Brinkhuis, Manje, Halldórsdóttir, Sara Lovísa, Ásgeirsdóttir, Tinna Laufey, Steingrímsdóttir, Hlíf, Danielsen, Ragnar, Dröfn Wessman, Inga, Kampanis, Petros, Hulcrantz, Malin, Durie, Brian G.M., Harding, Stephen, Landgren, Ola, Kristinsson, Sigurður Yngvi
• Other Authors: Faculty of Medicine, Other departments, Clinical Laboratory Services, Diagnostics and Blood Bank, Faculty of Psychology, Office of Division of Clinical Services I, Internal Medicine and Emergency Services, Faculty of Economics, Office of Division of Clinical Services II, Cardio-Vascular Center, Cancer Center, University of Iceland, Landspitali - The National University Hospital of Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2021
• Subjects: Mergæxli; Góðkynja einstofna mótefnahækkun; Kembileit; Hematology; Oncology; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/3099; https://doi.org/10.1038/s41408-021-00480-w

Funding Information: P.K. is an employee of The Binding Site. BGMD has done consultancy for Amgen, Janssen, Celgene, Takeda. S.H. is the director of The Binding Site. O.L. has received research funding from: National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. S.Y.K. has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. The remaining authors declare no competing interests. Funding Information: The iStopMM study is funded by the Black Swan Research Initiative by the International Myeloma Foundation and the Icelandic Centre for Research (grant agreement No 173857). Furthermore, this project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 716677). Screening tests are performed by The Binding Site Ltd. Birmingham, UK. Additional funding is provided by the University of Iceland, Landspítali University Hospital, and the Icelandic Cancer Society. Crosslinking of study data to national registries is performed by the Icelandic Directorate of Health and the Icelandic Cancer Society. The study is made possible by the hundreds of nurses, laboratory technicians, and physicians around Iceland who collect blood samples from participants for screening or during follow-up and provide clinical care that is not part of the study. Icelandic and International myeloma patient organizations including ...